Status:
ACTIVE_NOT_RECRUITING
Prognosis Impact of NSVTs After an AMI (TeVeO Study).
Lead Sponsor:
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Collaborating Sponsors:
Instituto de Salud Carlos III
Sanidad de Castilla y León
Conditions:
Death, Sudden
Ventricular Tachycardia
Eligibility:
All Genders
18+ years
Brief Summary
Nowadays, Sudden Cardiac Death (SCD) due to malignant arrhythmias is an important cause of death among acute myocardial infarction (AMI) survivors. Preventive strategies with implantable cardioverter-...
Detailed Description
INTRODUCTION Worldwide, cardiovascular diseases (CVD) are the leading cause of death, being responsible for nearly one out of three demises, and including pathologies with a huge impact in patients' a...
Eligibility Criteria
Inclusion
- AMI patients over 18 years old.
- LVEF equal or lower than 40% determined by a transthoracic echocardiography 4 days after the onset of the AMI.
- Revascularization during hospitalization according to the clinical practice guidelines
- Signed informed consent.
Exclusion
- Non-ischemic etiology of left ventricular dysfunction by cMRI.
- Patient already implanted with a cardiac device (pacemaker, ICD or ICD-TRC).
- Indication of pacemaker, ICD or ICD-TRC implantation during hospitalization.
- Allergy or hypersensitivity to any implatable device component.
- Contraindication for cMRI performance.
- Life expectancy under 1 year due to a non-cardiac cause.
- Concomitant valvulopathy with indication for surgery.
- High functional class (NYHA IV).
- No possibility to connect to the remote monitoring.
Key Trial Info
Start Date :
August 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT04765943
Start Date
August 15 2020
End Date
June 30 2025
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IBSAL-Hospital Universitario
Salamanca, Spain, 37007